Company Overview of AB2 Bio Ltd.
AB2 Bio Ltd. operates as a drug discovery and development company that specializes in developing therapies for the treatment of severe systemic inflammatory diseases. The company primarily focuses on developing drugs that treat the symptoms, as well as target the underlying causes of inflammation-based diseases. Its portfolio includes Interleukin-18 Binding Protein, a human protein with a high affinity for IL-18, a major inflammatory cytokine for inflammatory diseases treatment. The company was founded in 2010 and is based in Lausanne, Switzerland.
EPFL Innovation Park
Founded in 2010
41 21 693 82 80
41 21 693 82 81
Key Executives for AB2 Bio Ltd.
Similar Private Companies By Industry
|AB2 Bio Ltd.||Europe|
|ADC Products Switzerland SARL||Europe|
|ADC Therapeutics SA||Europe|
|AlloCyte Pharmaceuticals AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|NYC2012, Inc.||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact AB2 Bio Ltd., please visit www.ab2bio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.